Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Discov. 2012 Aug;2(8):666-9. doi: 10.1158/2159-8290.CD-12-0308.

RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.

Author information

1
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA.

Abstract

Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas.

PMID:
22886659
PMCID:
PMC5031078
DOI:
10.1158/2159-8290.CD-12-0308
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center